News | Heart Valve Technology | May 16, 2016

4Tech Partnering With Renowned Cardiologist to Accelerate Transcatheter Tricuspid Device Development

Company announces agreement with Jean-Claude Laborde to serve as R&D and clinical advisor

4Tech Inc., TriCinch transcatheter tricuspid valve repair device, Jean-Claude Laborde

Image courtesy of 4Tech Inc.

May 16, 2016 — 4Tech Inc. announced its partnership with Jean-Claude Laborde, M.D., as a research and development (R&D) and clinical advisor focused on fast-forwarding the TriCinch Generation Two and Generation Three programs. The company calls TriCinch the world’s first transcatheter device for repair of the tricuspid heart valve.

Laborde is an internationally recognized cardiologist and one of the world leaders in transcatheter aortic valve implantation (TAVI). He holds numerous patents for novel medical devices that have changed how cardiologists practice medicine and has designed new medical procedures to treat specific cardiac conditions. Laborde is a key opinion leader in interventional cardiology, having spoken around the world about TAVI and other new medical procedures and trained hundreds of physicians internationally.

Tricuspid regurgitation represents a significant unmet clinical need,” said Laborde, who previously supported the development of the CoreValve device when it was emerging, serving as chief medical officer until CoreValve was purchased by Medtronic in 2009. “4Tech is the sole company that is 100-percent-focused on repairing the tricuspid valve and possesses in-depth knowledge of the tricuspid valve anatomy and pathology. I am very proud to be a part of 4Tech.”

Laborde continues to provide proctoring support for TAVI devices. In addition, he has also been involved in training and teaching cardiologists and interventional cardiologists how to use TAVI devices, how to properly select patients and establish safe and effective protocols for hospitals and clinics. 

Laborde was also intimately involved in the development of the Transcatheter Mitral Valve Replacement solution developed by CardiAQ, which was acquired by Edwards Lifesciences in 2015.

For more information: www.4techtricuspid.com

Related Content

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
MitraClip Reduces Mortality for Heart Failure Patients With Secondary Mitral Regurgitation
News | Heart Valve Technology | September 26, 2018
Patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally...
Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Overlay Init